Details of the Drug

General Information of Drug (ID: DMSQZE2)

Drug Name
Asenapine
Synonyms
Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.8
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12.4 mL/min/kg [4]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 24 hours [4]
Metabolism
The drug is metabolized via the CYP1A2 and undergoes direct glucuronidation via UGT1A4 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.711 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [4]
Vd
The volume of distribution (Vd) of drug is 20-25 L/kg [7]
Chemical Identifiers
Formula
C17H16ClNO
IUPAC Name
(2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
Canonical SMILES
CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
InChI
InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
InChIKey
VSWBSWWIRNCQIJ-GJZGRUSLSA-N
Cross-matching ID
PubChem CID
3036780
ChEBI ID
CHEBI:71246
CAS Number
65576-45-6
DrugBank ID
DB06216
TTD ID
D00JRA
INTEDE ID
DR0146
ACDINA ID
D00045

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hyaluronidase (HYAL) TTXFI1K NOUNIPROTAC Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Asenapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Asenapine and Amisulpride. Schizophrenia [6A20] [40]
Coadministration of a Drug Treating the Disease Different from Asenapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Asenapine and Ivosidenib. Acute myeloid leukaemia [2A60] [41]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Asenapine and Midostaurin. Acute myeloid leukaemia [2A60] [42]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Asenapine and Arn-509. Acute myeloid leukaemia [2A60] [43]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Asenapine and Gilteritinib. Acute myeloid leukaemia [2A60] [42]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Asenapine and Oliceridine. Acute pain [MG31] [44]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Asenapine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [45]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Asenapine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [45]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Asenapine and Ivabradine. Angina pectoris [BA40] [43]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Asenapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [46]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Asenapine and Levalbuterol. Asthma [CA23] [47]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Asenapine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [48]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Asenapine and Eribulin. Breast cancer [2C60-2C6Y] [42]
Tucatinib DMBESUA Moderate Decreased metabolism of Asenapine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Asenapine and Bosutinib. Breast cancer [2C60-2C6Y] [42]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Asenapine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [42]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Asenapine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [50]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Asenapine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [47]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Asenapine and Pasireotide. Cushing syndrome [5A70] [42]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Asenapine and Osilodrostat. Cushing syndrome [5A70] [42]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Asenapine and OPC-34712. Depression [6A70-6A7Z] [51]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Asenapine and Esketamine. Depression [6A70-6A7Z] [52]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Asenapine and Deutetrabenazine. Dystonic disorder [8A02] [53]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Asenapine and Ingrezza. Dystonic disorder [8A02] [42]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Asenapine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [42]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Asenapine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [42]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Asenapine caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [52]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Asenapine and Levamlodipine. Hypertension [BA00-BA04] [54]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Asenapine and TAK-491. Hypertension [BA00-BA04] [54]
Givosiran DM5PFIJ Moderate Decreased metabolism of Asenapine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [55]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Asenapine and Belladonna. Infectious gastroenteritis/colitis [1A40] [51]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Asenapine and Polyethylene glycol. Irritable bowel syndrome [DD91] [42]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Asenapine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [43]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Asenapine and Crizotinib. Lung cancer [2C25] [56]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Asenapine and Ceritinib. Lung cancer [2C25] [42]
PF-06463922 DMKM7EW Moderate Increased metabolism of Asenapine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [57]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Asenapine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [58]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Asenapine and Osimertinib. Lung cancer [2C25] [59]
Capmatinib DMYCXKL Moderate Decreased metabolism of Asenapine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [55]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Asenapine and Selpercatinib. Lung cancer [2C25] [43]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Asenapine and Lumefantrine. Malaria [1F40-1F45] [52]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Asenapine and Vemurafenib. Melanoma [2C30] [42]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Asenapine and LGX818. Melanoma [2C30] [42]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Asenapine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [60]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Asenapine and Lasmiditan. Migraine [8A80] [61]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Asenapine and Panobinostat. Multiple myeloma [2A83] [62]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Asenapine and Siponimod. Multiple sclerosis [8A40] [52]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Asenapine and Fingolimod. Multiple sclerosis [8A40] [42]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Asenapine and Ozanimod. Multiple sclerosis [8A40] [63]
Olaparib DM8QB1D Moderate Increased metabolism of Asenapine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [52]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Asenapine and Rucaparib. Ovarian cancer [2C73] [42]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Asenapine and Triclabendazole. Parasitic worm infestation [1F90] [42]
Opicapone DM1BKA6 Moderate Antagonize the effect of Asenapine when combined with Opicapone. Parkinsonism [8A00] [64]
Abametapir DM2RX0I Moderate Decreased metabolism of Asenapine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [65]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Asenapine and Methylscopolamine. Peptic ulcer [DA61] [51]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Asenapine and Macimorelin. Pituitary gland disorder [5A60-5A61] [66]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Asenapine and Lefamulin. Pneumonia [CA40] [67]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Asenapine and Degarelix. Prostate cancer [2C82] [43]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Asenapine and Enzalutamide. Prostate cancer [2C82] [43]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Asenapine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [43]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Asenapine and LEE011. Solid tumour/cancer [2A00-2F9Z] [42]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Asenapine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [43]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Asenapine and Pitolisant. Somnolence [MG42] [42]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Asenapine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [42]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Asenapine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [68]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Asenapine and Lenvatinib. Thyroid cancer [2D10] [42]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Asenapine and Cabozantinib. Thyroid cancer [2D10] [43]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Asenapine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [51]
⏷ Show the Full List of 67 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sucralose E00370 71485 Flavoring agent
Gelatin E00630 Not Available Other agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Asenapine 10 mg tablet 10 mg Sublingual Tablet Oral
Asenapine 5 mg tablet 5 mg Sublingual Tablet Oral
Asenapine Maleate eq 2.5mg base tablet eq 2.5mg base Tablet Sublingual
Asenapine Maleate eq 5mg base tablet eq 5mg base Tablet Sublingual
Asenapine Maleate eq 10mg base tablet eq 10mg base Tablet Sublingual
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 22).
2 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
10 Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
24 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
25 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
26 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
27 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
28 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
29 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
30 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
31 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
32 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
33 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
34 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
35 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
36 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
37 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
38 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
39 Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.
40 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
41 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
42 Canadian Pharmacists Association.
43 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
45 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
46 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
47 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
48 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
49 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
50 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
51 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
52 Cerner Multum, Inc. "Australian Product Information.".
53 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
55 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
56 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
59 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
61 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
62 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
64 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
65 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
66 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
67 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
68 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.